JP7728265B2 - 甲状腺ホルモン受容体アゴニストとしての置換トリアジノン - Google Patents

甲状腺ホルモン受容体アゴニストとしての置換トリアジノン

Info

Publication number
JP7728265B2
JP7728265B2 JP2022542655A JP2022542655A JP7728265B2 JP 7728265 B2 JP7728265 B2 JP 7728265B2 JP 2022542655 A JP2022542655 A JP 2022542655A JP 2022542655 A JP2022542655 A JP 2022542655A JP 7728265 B2 JP7728265 B2 JP 7728265B2
Authority
JP
Japan
Prior art keywords
compound
alkyl
cycloalkyl
pharmaceutically acceptable
present application
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022542655A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023510835A (ja
JP2023510835A5 (cg-RX-API-DMAC7.html
Inventor
ジンジェ ジョウ
ジューシャン ジュー
ミンウェイ チョン
Original Assignee
エコジーン インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エコジーン インコーポレイテッド filed Critical エコジーン インコーポレイテッド
Publication of JP2023510835A publication Critical patent/JP2023510835A/ja
Publication of JP2023510835A5 publication Critical patent/JP2023510835A5/ja
Application granted granted Critical
Publication of JP7728265B2 publication Critical patent/JP7728265B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2022542655A 2020-01-13 2021-01-13 甲状腺ホルモン受容体アゴニストとしての置換トリアジノン Active JP7728265B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2020071741 2020-01-13
CNPCT/CN2020/071741 2020-01-13
CN2020107757 2020-08-07
CNPCT/CN2020/107757 2020-08-07
PCT/CN2021/071381 WO2021143706A1 (en) 2020-01-13 2021-01-13 Substituted triazinones as thyroid hormone receptor agonists

Publications (3)

Publication Number Publication Date
JP2023510835A JP2023510835A (ja) 2023-03-15
JP2023510835A5 JP2023510835A5 (cg-RX-API-DMAC7.html) 2024-01-25
JP7728265B2 true JP7728265B2 (ja) 2025-08-22

Family

ID=74418122

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022542655A Active JP7728265B2 (ja) 2020-01-13 2021-01-13 甲状腺ホルモン受容体アゴニストとしての置換トリアジノン

Country Status (9)

Country Link
US (3) US11780825B2 (cg-RX-API-DMAC7.html)
EP (1) EP4090652A1 (cg-RX-API-DMAC7.html)
JP (1) JP7728265B2 (cg-RX-API-DMAC7.html)
CN (1) CN115244037B (cg-RX-API-DMAC7.html)
AU (1) AU2021208027B2 (cg-RX-API-DMAC7.html)
IL (1) IL294494A (cg-RX-API-DMAC7.html)
MX (1) MX2022008626A (cg-RX-API-DMAC7.html)
WO (1) WO2021143706A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202207541B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020227549A1 (en) 2019-05-08 2020-11-12 Aligos Therapeutics, Inc. MODULATORS OF THR-β AND METHODS OF USE THEREOF
MX2022008626A (es) 2020-01-13 2022-08-22 Eccogene Shanghai Co Ltd Triazinonas sustituidas como agonistas del receptor de la hormona tiroidea.
EP4168384A4 (en) 2020-06-17 2024-07-10 Autobahn Therapeutics, Inc. THYROMIMETICS
EP4167986A4 (en) 2020-06-17 2024-11-20 Autobahn Therapeutics, Inc. THYROMIMETICS
JP2023549332A (ja) * 2020-11-06 2023-11-24 アリゴス セラピューティクス,インコーポレーテッド 甲状腺ホルモン受容体調節剤としての2-ピリドン
CN114685450B (zh) * 2020-12-30 2026-06-16 昆药集团股份有限公司 2-吡啶酮类衍生物及其制备方法和在医药上的应用
CN117624069A (zh) * 2022-08-19 2024-03-01 凯思凯迪(上海)医药科技有限公司 一种多环类甲状腺激素β受体激动剂及其用途
CN118146123A (zh) * 2024-02-04 2024-06-07 河北鼎泰制药有限公司 一种盐酸安罗替尼中间体的合成方法
WO2026067791A1 (en) * 2024-09-30 2026-04-02 Ascletis Pharma (China) Co., Limited 2-phenyl-1,2,4-triazine-3,5(2h,4h)-dione derivatives as thr-beta agonist or modulators for the treatment of obesity
WO2026092583A1 (en) 2024-10-30 2026-05-07 Ascletis Pharma (China) Co., Limited Thr-beta modulators, alone or in combination with glp-1r\gipr\gcgr modulators for the treatment of metabolic diseases and alopecia areata diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012106996A (ja) 2010-10-19 2012-06-07 Mitsubishi Tanabe Pharma Corp 新規甲状腺ホルモンβ受容体作動薬

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE60020786T2 (de) 1999-09-30 2006-03-23 Pfizer Products Inc., Groton 6-Azauracilderivate als Liganden der Thyroidrezeptoren
ES2267945T3 (es) 2001-05-31 2007-03-16 Pfizer Products Inc. Uso medico de compuestos tiromimeticos para tratar la perdida del cabello y composiciones.
ATE480524T1 (de) 2005-07-21 2010-09-15 Hoffmann La Roche Pyridazinonderivate als schilddrüsenhormon- rezeptoragonisten
US8076334B2 (en) 2007-09-20 2011-12-13 Hoffmann-La Roche Inc. Prodrugs of thyroid hormone analogs
KR101396606B1 (ko) * 2009-04-20 2014-05-16 미쓰비시 타나베 파마 코퍼레이션 신규 갑상선 호르몬 β 수용체 작동약
CN109574995B (zh) 2018-01-23 2020-07-24 深圳市塔吉瑞生物医药有限公司 取代的哒嗪酮化合物
ES3029158T3 (en) 2018-06-12 2025-06-23 Xizang Haisco Pharmaceutical Co Ltd Thyroid hormone receptor agonists and uses thereof
CN119431265A (zh) * 2019-02-21 2025-02-14 南京瑞捷医药科技有限公司 一种作为甲状腺激素受体激动剂的化合物
MX2022008626A (es) 2020-01-13 2022-08-22 Eccogene Shanghai Co Ltd Triazinonas sustituidas como agonistas del receptor de la hormona tiroidea.
EP4167986A4 (en) * 2020-06-17 2024-11-20 Autobahn Therapeutics, Inc. THYROMIMETICS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012106996A (ja) 2010-10-19 2012-06-07 Mitsubishi Tanabe Pharma Corp 新規甲状腺ホルモンβ受容体作動薬

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DANZI, S. et al.,Hormone and Metabolic Research,2011年,Vol. 43,No. 11,p. 737-742
JOHARAPURKAR, Amit A. et al.,Journal of Medicinal Chemistry,2012年,Vol. 55,No. 12,p. 5649-5675
LIU, Huanxiang et al,Bioorganic & Medicinal Chemistry,2007年,Vol. 15,No. 15,p. 5251-5261

Also Published As

Publication number Publication date
CA3164404A1 (en) 2021-07-22
US12291518B2 (en) 2025-05-06
KR20220128383A (ko) 2022-09-20
WO2021143706A1 (en) 2021-07-22
IL294494A (en) 2022-09-01
CN115244037B (zh) 2024-10-25
US20250320197A1 (en) 2025-10-16
CN115244037A (zh) 2022-10-25
MX2022008626A (es) 2022-08-22
JP2023510835A (ja) 2023-03-15
AU2021208027B2 (en) 2025-10-16
US20240190846A1 (en) 2024-06-13
US20210230146A1 (en) 2021-07-29
US11780825B2 (en) 2023-10-10
EP4090652A1 (en) 2022-11-23
ZA202207541B (en) 2024-12-18
AU2021208027A1 (en) 2022-07-28

Similar Documents

Publication Publication Date Title
JP2023510835A (ja) 甲状腺ホルモン受容体アゴニストとしての置換トリアジノン
JP7569443B2 (ja) テトラヒドロピラゾロ-ピラジニル-ジヒドロイミダゾロンまたはテトラヒドロピラゾロ-ピリジニル-ジヒドロイミダゾロン化合物およびそれを使用する方法
JP7811578B2 (ja) 中環状または大環状ベンジル置換複素環誘導体およびオレキシン-2受容体アゴニストとしてのそれらの使用
WO2023029380A1 (zh) 作为glp1r激动剂的新型芳醚取代杂环类化合物
CN110461830B (zh) Jak1选择性抑制剂
CN114478497A (zh) 芳基烷基酸类glp-1受体激动剂及其用途
WO2020147739A1 (zh) 溶血磷脂酸受体拮抗剂及其制备方法
CN104066729A (zh) 溶血磷脂酸受体拮抗剂
CN104093705A (zh) 新的氮杂环丁烷衍生物、其药物组合物及其用途
CN108863850B (zh) 联芳基类化合物及其制备方法和用途
CN104903296A (zh) 二氢吡唑gpr40调节剂
CN115413279A (zh) P2x3调节剂
WO2022143574A1 (zh) 2-吡啶酮类衍生物及其制备方法和在医药上的应用
TW201609734A (zh) 用於治療寄生蟲疾病之化合物及組合物
TW201529557A (zh) Cxcr7受體調節劑
WO2018145653A1 (zh) 联芳基类化合物及其制备方法和用途
KR102734880B1 (ko) 항바이러스 활성을 갖는 아마이드 유도체
JP7703272B2 (ja) Ssao阻害剤およびその使用
CN111372928A (zh) 用作钾通道抑制剂的苯并咪唑衍生物
WO2022033303A1 (zh) 苄胺类衍生物及其制备方法与用途
CA3164404C (en) Thyroid hormone receptor agonists and uses thereof
CN109206360A (zh) 咔唑酰胺类衍生物或其盐及其制备方法和用途
HK40127587A (en) Pcsk9 inhibitors and methods of use thereof
WO2025252247A1 (zh) Gspt1降解剂抗体偶联物
WO2017089389A1 (en) Trypanosomes inhibitors

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241219

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250317

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250529

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20250530

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250731

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250812

R150 Certificate of patent or registration of utility model

Ref document number: 7728265

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150